Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Apollomics Starts Global Phase II Trial of c-MET Inhibitor

publication date: May 22, 2020

Apollomics, a US-China biopharma, will start a global Phase II trial of its c-MET inhibitor in two indications: non-small cell lung cancer (NSCLC) patients with a mutation that leads to MET exon 14 skipping, and patients who have any tumor type with MET amplification or fusions. In its Phase I trial, APL-101 was found to be safe in NSCLC and GBM patients with c-MET dysregulations. APL-101 is being developed in China by Beijing Pearl Biotechnology, Apollomics' China partner. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China